SGI-DNA Inc., a Synthetic Genomics Inc. (SGI) company, announced the launch of Next-Generation Sequencing (NGS) Library Construction Kits for the BioXp 3200 System, enabling researchers to automate even more processes in the genomics research continuum.

With the new kits, scientists can now prepare DNA samples for NGS applications on the BioXp 3200 System. The automation of essential steps in “reading” and “writing” DNA on a single compact workstation has the potential to accelerate life science research, as scientists will have more time to focus on other downstream applications. Practical applications of genomics range from better understanding of human disease to improving crop resistance and increasing the global food supply under drought conditions. The BioXp 3200 System will continue to innovate and automate genomics research to accelerate discovery, with plans to expand to RNA and protein synthesis.

“BioXp system users can now automate more of their genomic workflow, allowing them to discover and study more genes and their functions,” said Nathan Wood, president, SGI-DNA. “We are anticipating more breakthroughs in both applied and academic life science research as scientists will focus on analyzing larger data sets.”

NGS technologies have revolutionized the study of nearly all forms of life by enabling scientists to sequence whole genomes of organisms and allowing for further investigation into the functions of genes, proteins, and biochemical pathways. Synthetic Genomics has made major contributions to this field with the invention of revolutionary gene synthesis technologies and the development of the first synthetic cell in 2009. DNA technologies developed during the synthetic cell project, including the Gibson Assembly method, are incorporated into the design of the BioXp 3200 System, which is currently installed at more than 50 biotechnology, pharmaceutical, and academic institutions.

SGI-DNA, a wholly-owned subsidiary of Synthetic Genomics, Inc. (SGI), is responsible for all commercial aspects of SGI’s synthetic DNA business and focuses on strategic business relationships with both academic and commercial researchers.